Active Surveillance of Follow-on Biologics: A Prescription for Uptake
As lower-cost versions of original biologic drugs made by different manufacturers, follow-on biologics offer the promise of meaningful savings for the US health care system and improved patient health outcomes through greater medication adherence. Fulfillment of this promise, however, is predicated on the prescribing of such products. Under state drug product selection laws, pharmacists may substitute prescriptions for brand name, small-molecule drugs with their generic equivalents, but will be indefinitely prohibited from substituting prescriptions for original biologics with their follow-on biologic counterparts given a lack of product-specific guidance on demonstrating interchangeability. Even when interchangeable follow-on biologics become available, they will face heightened barriers to substitution following the enactment of so-called carve-outs in several states. Data collected to date suggest that a substantial proportion of US physicians remain skeptical of follow-on biologics despite their long record of safe and effective use in Europe. Active surveillance of follow-on biologics within the US market using insurance claims databases can help address this skepticism and help answer key questions concerning the safety of switching between original and follow-on products or between different follow-on products, and of extrapolating to broader indications. Funding is needed to support such surveillance activities and to disseminate the findings to key stakeholders.
- 1.Observations on trends in prescription drug spending. ASPE Issue Brief. March 8, 2016. https://aspe.hhs.gov/sites/default/files/pdf/187586/Drugspending.pdf. Accessed 4 Oct 2016.
- 2.Patient Protection and Affordable Care Act, Pub. L. No. 111–148, Title VII, Subtitle A, 124 Stat. 119, 804–21 (2010).Google Scholar
- 3.Westgate A. Five specialty pharmaceutical trends to watch. Managed Healthcare Executive. October 5, 2016. http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/five-specialty-pharmaceutical-trends-watch. Accessed 5 Oct 2016.
- 4.Delivering on the potential of biosimilar medicines. IMS Institute for healthcare Informatics. March 2016. http://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/Documents/IMS_Institute_Biosimilar_Brief_March_2016.pdf. Accessed 4 Oct 2016.
- 7.Reading the signs: a roadmap for engaging physicians in the biosimilar discussion. Quantia. August 15, 2015. http://cdn2.hubspot.net/hubfs/436920/Whitepaper_-_Quantia_-_Reading_the_Signs_August_2015.pdf. Accessed 4 Oct 2016.
- 12.42 U.S.C. § 262.Google Scholar
- 14.Mass. Gen. Laws ch. 112, § 12D.Google Scholar
- 15.Mass. Gen. Laws ch. 112, § 12EE.Google Scholar
- 16.Del. Code Ann. tit.24, § 2549.Google Scholar
- 17.Del. Code Ann. tit.24, § 2549A.Google Scholar
- 18.Ga. Code Ann. § 26-4-81.Google Scholar
- 19.N.C. Gen. Stat. § 90-85.28.Google Scholar
- 24.Gagne JJ, Kesselheim AS, Choudhry NK, Polinski JM, Hutchins D, Matlin OS, et al. Comparative effectiveness of generic versus brand-name antiepileptic medications. Epilepsy Behav. 2015;52(Pt A):14–8.Google Scholar
- 25.Medicare program; revisions to payment policies under the physician fee schedule and other revisions to Part B for CY 2016. Proposed rule. 80 Fed Regist. 2015;80:41686.Google Scholar
- 26.42 U.S.C. § 1395w-3a.Google Scholar
- 27.Medicare program; revisions to payment policies under the physician fee schedule and other revisions to Part B for CY 2016. Final rule with comment period. 80 Fed Regist. 2015;80:70886.Google Scholar
- 28.Implementation of biosimilar claim modifiers. Centers for Medicare and Medicaid Services. https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R1542OTN.pdf. September 4, 2015. Accessed 4 Oct 2016.
- 29.Neupogen: highlights of prescribing. FDA. July 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103353s5186lbl.pdf. Accessed 5 Oct 2016.
- 30.Zarxio: highlights of prescribing. FDA. March 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125553lbl.pdf. Accessed 5 Oct 2016.
- 32.Biologics and biosimilars collective intelligence consortium. Academy of Managed Care and Pharmacy. http://www.amcp.org/BBCIC/. Accessed 7 Nov 2016.
- 34.Avoidable costs in U.S. health care. IMS Institute for Healthcare Informatics. June 2013. http://www.imshealth.com/files/web/IMSH%20Institute/Reports/Avoidable_Costs_in%20_US_Healthcare/IHII_AvoidableCosts_2013.pdf. Accessed 4 Oct 2016.
- 35.Effects of therapeutic class on generic drug substitution. Department of Health and Human Services. April 25, 2014. http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-14-014.html. Accessed 4 Oct 2016.
- 36.Educating groups influencing generic drug use. Department of Health and Human Services. March 25, 2015. http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-15-013.html. Accessed 4 Oct 2016.